AVTX (Avalo Therapeutics) Current Accrued Expense: $14.74 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVTX Avalo Therapeutics Inc AVTX
24 GF Score
Price $19.85
GF Value $0.20
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Avalo Therapeutics Current Accrued Expense?

Avalo Therapeutics AVTX +0.05% 24 Current Accrued Expense is $14.74 Mil as of Jun. 2026. GuruFocus rates AVTX with a GF Score™ of 24/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Avalo Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $14.74 Mil.

Avalo Therapeutics's quarterly Current Accrued Expense increased from Dec. 2025 ($7.95 Mil) to Mar. 2026 ($8.84 Mil) and increased from Mar. 2026 ($8.84 Mil) to Jun. 2026 ($14.74 Mil).

Avalo Therapeutics's annual Current Accrued Expense declined from Dec. 2023 ($3.06 Mil) to Dec. 2024 ($2.54 Mil) but then increased from Dec. 2024 ($2.54 Mil) to Dec. 2025 ($7.95 Mil).

Avalo Therapeutics Current Accrued Expense Related Terms

Avalo Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Current Accrued Expense Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.34 9.00 3.06 2.54 7.95

Avalo Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 3.35 7.95 8.84 14.74
AVTX
24GF Score
Avalo Therapeutics Inc AVTX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $14.74 Mil mean?
Avalo Therapeutics (AVTX) has a Current Accrued Expense of $14.74 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Current Accrued Expense too high?
Avalo Therapeutics' current Current Accrued Expense is $14.74 Mil. Overall, Avalo Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Current Accrued Expense compare to MRVI and LBRX?
Avalo Therapeutics' Current Accrued Expense of $14.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Current Accrued Expense is $14.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $19.85 — trading 9825% above its estimated fair value. The current Current Accrued Expense is $14.74 Mil. Avalo Therapeutics' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Current Accrued Expense is $14.74 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $19.85 is trading 9825% above its estimated GF Value™ of $0.20. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Current Accrued Expense: $14.74 Mil
  • GF Value™: $0.20 vs. price of $19.85 (9825% above fair value)
  • GF Score™: 24/100 with 7 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
24GF Score

Get the complete analysis for AVTX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.85
Price
$0.20
GF Value